Verified employee & interview reviews

Tata 1mg Reviews

Gurugram, Haryana

4.0/ 5

2 reviews

Tata 1mg, formerly known as 1mg, is a leading Indian digital consumer healthcare platform headquartered in Gurugram, Haryana. Established in April 2015 by co-founders Prashant Tandon, Gaurav Agarwal, and Vikas Chauhan, the company originated as a spin-off from HealthKart's generic drug search business, HealthkartPlus. In June 2021, Tata Digital Limited acquired a majority 55% stake in the startup, leading to its strategic rebranding under the iconic Tata umbrella. By 2023, Tata 1mg solidified its market presence by overtaking competitors to become India's top e-pharmacy platform, maintaining a dominant market share of over 30%. The company operates a comprehensive, multi-channel business model divided into several core verticals: e-pharmacy, e-diagnostics, tele-consultation, and curated health content. Through its robust digital platform, which includes a web portal and mobile applications, Tata 1mg provides home delivery services for prescription and over-the-counter (OTC) medicines across more than 1,000 cities and 20,000 pin codes in India. This supply chain network is supported by over 30 temperature-controlled warehouses and fulfillment centers alongside an expanding fleet of brick-and-mortar retail stores. In the diagnostics and laboratory vertical, Tata 1mg manages an integrated network of NABL-certified diagnostic labs, serving dozens of cities with hundreds of phlebotomists conducting at-home sample collections. The platform allows users to book preventive health packages and access verified, expert-curated medical details concerning drug side effects and cost-effective substitutes. Additionally, the company offers virtual consultations with certified doctors across more than 20 medical specialties. In recent years, Tata 1mg has expanded into highly specialized care areas, creating a comprehensive cancer care platform, introducing adult vaccination-at-home services, and managing numerous patient support programs in partnership with international pharmaceutical manufacturers. It has also successfully introduced private-label health, nutrition, and wellness products, including its proprietary Ayurvedic brand, Tejasya, and vitamin sublingual sprays launched in collaboration with Vitonnix UK. Financially, Tata 1mg operates as a heavily backed private entity under Tata Digital, having raised over $230 million from high-profile global investors such as HBM Healthcare Investments, the International Finance Corporation (IFC), and the Bill & Melinda Gates Foundation, pushing its valuation past the $1.25 billion milestone. For the fiscal year 2024, the company reported operational revenues of INR 1,968 crore, and by fiscal year 2026, it successfully achieved positive EBITDA across its core business units, with its diagnostics division alone surpassing an annual revenue run rate of INR 600 crore. Led by CEO Prashant Tandon, the organization employs thousands of professionals across corporate offices and medical infrastructure, emphasizing internal principles like flat hierarchies and individual accountability to sustain its vision of making healthcare affordable, transparent, and accessible to a billion Indian consumers.